TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Advanced Science reports that STING signaling in bone marrow macrophages is activated during aging in mice and is linked to bone loss. The findings point to a possible research target, but do not show that blocking STING prevents osteoporosis in people.
Researchers have linked activation of the STING pathway in bone marrow immune cells to age-related bone loss in mice, identifying a possible target for future osteoporosis research. The study, published in Advanced Science, connects signals from aging marrow fat cells to inflammation and reduced bone-forming capacity, but it does not establish a treatment or preventive approach for people.
The research focused on bone marrow macrophages, immune cells that help defend against pathogens and can also contribute to inflammation. The researchers found that STING signaling in these cells increased with age. STING is part of the innate immune system, which responds to infection, cellular stress and other threats.
In experiments involving mice whose bone marrow cells lacked STING, the effects differed by age. These mice had reduced bone density when young, but were protected against bone loss later in life, according to the report. That contrast suggests the pathway’s role may change as the bone marrow ages; it also cautions against assuming that blocking STING would have the same effect at every life stage.
The team also examined bone marrow adipocytes, or marrow fat cells. When cells isolated from older mice were cultured with macrophages from young mice, the fat cells promoted STING activation. Researchers identified the protein DPP4, secreted by the fat cells, as a factor that activated the pathway and contributed to inflammation and bone loss in the study model.
Further downstream, STING activation was associated with depletion of NAD+ in surrounding marrow cells. NAD+ supports several cellular processes, including metabolism and DNA repair. The report says lower NAD+ in bone marrow stem cells interfered with their ability to differentiate into cells that form and repair bone, providing a proposed link between inflammation and declining bone formation.
Osteoporosis involves weakened bones and a higher risk of fractures, and age-related changes in the bone marrow are one area researchers are investigating. This study offers a possible chain of events: aging marrow fat cells release DPP4, macrophage STING signaling rises, NAD+ declines, and stem cells become less able to support bone formation. The work matters because it connects several cell types and processes in one model, rather than treating bone loss as the result of a single cell population.
That pathway may help guide research into ways of limiting age-related bone deterioration. However, the findings are preclinical: they come from mouse experiments and cell cultures, not a clinical trial. They do not show that a STING-targeting drug can prevent osteoporosis, reduce fractures or be used safely in people. The results support further investigation, not a change to current prevention or treatment decisions.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Fitbit Sense 2 Smartwatch – Blue Mist / Pale Gold
As an affiliate, we earn on qualifying purchases.
How the Study Traced Marrow Signals
The study, by Li and colleagues, was published in Advanced Science in 2026 under the title “Bone Marrow Macrophage STING Signaling is a Direct Nexus Linking Marrow Adipose Expansion to NAD+ Depletion and Osteogenic Decline in Skeletal Aging.” Its central question was how the STING pathway, already known for its role in innate immune responses, functions in the aging bone marrow.
The researchers used mice lacking STING in bone marrow cells and compared the effects at different ages. They then tested interactions between marrow adipocytes from older mice and macrophages from young mice, and examined what happened after pathway activation. The report describes the work as linking three cell types—adipocytes, macrophages and bone marrow stem cells—through a series of signals associated with skeletal aging.
The authors characterized macrophage STING signaling as an “integration hub” for changes in the complex marrow environment. That phrase reflects the researchers’ interpretation of their findings; it is not evidence that STING is the sole driver of osteoporosis or that its inhibition will work as a therapy.
“Consequently, these findings position STING signaling in bone marrow macrophages as a pivotal integration hub, highlighting its targeting potential for comprehensive management of the complex bone marrow microenvironment during skeletal aging.”
— The study authors, as quoted in the News-Medical report
Human Benefits Remain Untested
The report describes experiments in mice and cultured cells. It does not provide evidence that the same DPP4-STING-NAD+ sequence drives bone loss in humans, or that targeting STING would prevent osteoporosis or fractures in patients. The reported findings also do not establish what form of STING inhibition, dose or treatment timing might be appropriate.
The differing bone-density effects in young and older mice leave open how age and other biological conditions shape the pathway’s role. The source material does not give detailed effect sizes, participant data or clinical outcomes, and there is no human trial result described. Further studies will be needed to test whether the proposed mechanism translates beyond the mouse model and whether interfering with this immune pathway has acceptable risks.
Testing the Pathway Beyond Mice
The immediate next step is further research to validate the proposed sequence in additional models and determine whether DPP4, STING activation and NAD+ depletion are linked in human aging bone. Researchers would also need to examine whether altering the pathway can preserve bone without disrupting STING’s normal role in immune defense.
No clinical trial, approved therapy or timeline for human testing is identified in the supplied report. Until evidence from human studies is available, the findings should be treated as a possible direction for research rather than a basis for changing osteoporosis care. People making decisions about bone health should consult a qualified health professional.
Key Questions
What did the study find?
In mice, researchers linked age-related activation of STING in bone marrow macrophages with inflammation, NAD+ depletion and reduced capacity for bone formation. They also identified DPP4 from aging marrow fat cells as a factor that activated STING in their experiments.
Does the study show that a STING drug prevents osteoporosis in people?
No. The report describes mouse and cell-culture research. It does not establish that targeting STING prevents osteoporosis or fractures in humans.
Why did the effects differ between young and older mice?
Mice lacking STING in bone marrow cells had lower bone density at a young age but were protected against bone loss later in life. The report indicates that the pathway’s effects may depend on age, but does not fully explain the difference.
What role did DPP4 and NAD+ play?
The researchers reported that DPP4 secreted by older marrow fat cells activated STING in macrophages. Downstream, STING activation was associated with lower NAD+ in nearby marrow cells, which impaired stem-cell differentiation needed for bone formation in the study model.
What happens next?
Further studies are needed to test the mechanism, assess safety and determine whether the findings apply to people. The supplied report does not identify a clinical trial or a timeline for human testing.
Source: rss
